STATinMED Real World Data Insights (USA)

Field Names
Records
Coordinating Country
United States
Region

All 50 states and US territories, including Hawaii, Alaska, and Puerto Rico

Brief Database Description

STATinMED’s licensed all-payer medical, and pharmacy claims dataset (STATinMED Real World Data Insights) provides insight into approximately 80% of the US healthcare system. These data are comparable with other all-payer claims repositories as they are sourced directly from claims clearinghouses, which are responsible to manage claims transactions between payers and providers, offering comprehensive coverage at the patient level across the US healthcare system. All provider types are available in near-real-time to support a variety of evidence generation needs. 

Key Features include: 
- Patient Universe: 300 million unique patients, de-identified, tokenized; HIPAA-compliant;
- Real-Time Data: Repository from 2014 to most current quarter (1-month data lag);
- Rapid Access: No delay or interruption to data access, and the project can kick-off two (2) weeks after contract execution;
- Care Settings: Longitudinal tracking across data sources, pharmacy, and sites of care (inpatient, outpatient, accountable care organizations/facilities);
- Nationwide Reach: Patients from all US geographic regions, including Hawaii, Alaska, and Puerto Rico;
- Patient Tracking: Linked via direct matching algorithm;
- Payer Detail: In-depth visibility into payer account details at transaction level;
- Providers & Prescriptions: Providers include 97% healthcare provider specialties (physician assistant, nurse practitioner, registered nurse); full life cycle of pharmacy and prescription claims;
- Channel Capture: Commercial, Medicare Fee-for-Service (FFS) & Advantage, Medicaid covering all 50 states with ability to track patients across insurance plans and channels;
- Social Determinants of Health: Race, household income bracket, education (where available) data collected from aggregation of 5 sources of national consumer marketing data; data provide insights into key social determinants of health for ~70% of patients captured.

Database Type
Longitudinal Population Database
- Drug and Diagnosis Data
- - Medical and Pharmacy Insurance Claims
- - - Outpatient and inpatient
Database Source
Medical Insurance Claims
EHR/EMR
Medical Records
Other

(All-payer pharmacy claims)

Frequency of Data Collection
Ongoing
Frequency of Data Update
Quarterly
Years Covered
2014 - Present

(Data are available starting January 1, 2014; however, there is a 30-day lag)

Population Type
Outpatient/Non-Institutionalized
Inpatient
Insured
Emergency Room (ER/ED) Population

[Data include claims for de-identified patients with Commercial, Medicare and Medicaid (FFS and Advantage) insurance coverage]

Patient Type
Inpatient and Outpatient
Emergency Room (ER/ED)
Other

[Inpatient and Outpatient
Emergency Room (ER/ED)
ER/ED claims available, as well as long-term care, home health agency, and durable medical equipment (DME) claims]

Date of Last Update
Ongoing

STATinMED Real-World Data Insights is updated on an ongoing basis.
This profile was developed for the B.R.I.D.G.E. TO DATA site on August 16, 2023.

Field Names
Records
Database Population Size
> 100 Million

(Approximately 300 Million)

Active Population Size
> 100 Million

(Approximately 300 Million; the number is contingent on patient needs)

Annual Change in Population
N/A

(This information is not available as it is very difficult to assess the database population in entirety per year, especially due to the pandemic. Besides, the database is dynamic with people entering based on claims, or leaving, due to death. Please contact database manager if you need more details.)

Sample Weights - Extrapolation Factors
Yes

Weighting can be performed and is based on a particular study.

Final Population Size
N/A

(Not applicable as data are still being collected)

Field Names
Records
Age of Patients at Data Collection
Yes

Year of birth is captured

Approximate Percentage of Participants <18 years and those >65 years

< 18 years = 23.5%
> 65 years = 16.9%

(Based on overall data; percentages are similar to the overall US population)

Gender Data
Yes

(Sex at birth information)

Percentage of Males/Females

Males = 49%
Females = 51%

(Percentages are similar to the overall US population)

Ethnicity / Race Data
Yes
Geographic Location

All 50 states and US territories, including Hawaii, Alaska, and Puerto Rico

Date of Birth Recorded
No
Death Recorded
Yes

(Please contact database manager for more details)

Availability of death certificate / autopsy information
No
Other Demographic Data
Yes

Information is available on income, education level, household income bracket. However, information on quality of care is not recorded.

Field Names
Records
Physician ID
Yes
Physician Specialty
Yes
Pharmacy ID
No
Field Names
Records
Diagnosis Data
Yes

Diagnosis claims are available from January 1, 2014; however, no patient-reported outcomes are available
NOTE: Disease severity and quality of life can be assessed based on statistical analysis

Diagnoses Coded
DRG
DSM-IV
ICD-10
ICD-10-CA
ICD-10-CM
ICD-9
ICD-9-CM
ICD-O-2
ICD-O-3
Diagnoses: Date Parameters
2014 - Present

(Data are available starting January 1, 2014; however, there is a 30-day lag)

Diagnoses: Maximum Number of Codes Allowed
Varies; however, there is no maximum
Physical Examination Findings
Yes

However, only if a claim is captured at physical examination; analyzable format (e.g., codes on claims).
Pregnancy, allergy, fever claims can all be captured via claims codes; however, vital signs (height, weight, BMI, respiratory rate) are not captured in claims.

Birth Defect Data
Yes
Cancer Data
Yes

Cancer type and treatment and related claims are available; however, stage, pathology, tumor markers are not available in claims.

Infectious Disease Data
Yes

Diagnosis and treatment claims are available; test occurrences are available, but not test results.

Environmental Exposures
Yes

However, only if exposure can be captured using claims

Behavioral Data Elements
Yes

(Please contact database manager for more details)

Field Names
Records
Procedure Data
Yes

Claims for procedures are captured

Procedures Coded
CPT
CPT-4
HCPCS
ICD-9
ICD-9-CM
ICD-10
ICD-10-CM
ICD-10-PCS
LOINC
Number of Procedures Coded
Unlimited
Procedure Date Parameters
2014 - Present

(Data are available starting January 1, 2014; however, there is a 30-day lag)

Laboratory Information
Yes

Test orders, tests performed are available; however, test results are not available

Field Names
Records
Drug Data
Yes: Prescription only
Drug Date Parameters
2014 - Present

(Data are available starting January 1, 2014; however, there is a 30-day lag)

Drug Regimen & Route
Yes

Information is available on medication delivery and dose information

Drug Manufacturer
Yes
Drug Dosage
Yes

Dose information is available

Drug Days Supply
Yes

Days of supply information is available

Drug Coding System: Maximum Number
Unlimited

(Varies by patient)

Drug Coding System: Primary
HCPCS (Level I, II or III codes)
Medispan Diagnostic Codes (MDDX)
NDC
Drug Coding System: Other
N/A

(Not applicable)

Drug Generic Name
Yes
Drug Additional Information
Yes

Information is available on cost, indication for therapy, and total number of prescriptions for recent 1 year (with a one-month lag)

Field Names
Records
Biobank Type
N/A
Human Specimen
N/A
Blood Type
N/A
Biomarkers
N/A
Patient ID
N/A
Number of Samples
N/A
Frequency of Sample Collection
N/A
Pre-diagnostic Sample Collection
N/A
Post-treatment Sample Collection
N/A
Method of Sample Collection
N/A
Age at Sample Collection
N/A
Date of Sample Collection
N/A
Reason for Sample Collection
N/A
Method of Sample Storage
N/A
Length of Sample Storage
N/A
Pathology
N/A
DNA Isolation
N/A
RNA Isolation
N/A
Cell Culture
N/A
Genetic Testing
N/A
Access for Research: Specimens
N/A
Access for Research: Genetic Data
N/A
Access for Research: Epidemiologic Data
N/A
Quality Assurance Procedures
N/A
Family History
N/A
Medical History
N/A
Biobank Linkage
N/A
Field Names
Records
Type of Genetic Database
N/A
Source of Genetic Data
N/A
Specimen Genotyped
N/A
Tissue Form
N/A
Genetic Template
N/A
Gene-Drug Response
N/A
Gene-Disease Relationship
N/A
Gene-Health Outcome Relationship
N/A
Gene-Environment Response
N/A
Method of Imputing Genetic Data
N/A
Genetic Variant Identification
N/A
Genetic Data Level
N/A
Genotyping Method
N/A
Method of Genetic Variant Filtering
N/A
Haplotypes
N/A
Haplogroups
N/A
Variable Number of Tandem Repeats (VNTR)
N/A
Single Nucleotide Polymorphisms (SNPs)
N/A
Variant Type
N/A
Variant Class
N/A
Mutation Indicated
N/A
Position
N/A
Amino Acid Change
N/A
Genotype / Polymorphism
N/A
Allele Frequency
N/A
Linkage Disequilibrium (r²)
N/A
Noncarriers Indicated
N/A
Association Statistics
N/A
Genetic Relatedness Pairing
N/A
Data Sharing: Genetic Data
N/A
Access for Research
N/A
Genetic Data Linkage
N/A
Description of Genetic Data Linkage
N/A
Field Names
Records
Cost Data
Yes

(Please contact database manager for more details)

Cost Denomination
United States Dollar (USD)
Type of Cost Data
Yes

(Please contact database manager for more details)

Surrogate Cost Data Link
No
Description of Surrogate Link
N/A

(Not applicable)

Field Names
Records
Data Validation Against Original Source
Yes

These data are validated, as they are sourced directly from claims clearinghouses, which are responsible for managing claims transactions between payers and providers, offering comprehensive coverage at the patient level across the US healthcare system.

Access to Medical Records
Yes

Data access is restricted by licensing agreement; please contact database manager for more details.
NOTE: Data are restricted to de-identified healthcare claims, e.g., patient identifiers are removed.

Linkage to Other Databases
Yes

Data can be linked to other sources (e.g., EMR/EHR) as applicable, based on project objectives.
NOTE: The data do not have OMOP conversion capabilities.

Brief Description of Linkage Capabilities

Data can be linked to other sources (e.g. EMR/EHR) as applicable, based on project objectives. Tokenization is available.

Field Names
Records
Database Contact Data

Keshia Maughn
SVP/Principal, RWE (STATinMED RWD Insights)
STATinMED, LLC
13101 Preston Rd Suite 110, #3395
Dallas, TX 75240
USA
Phone:+1 214-480-4946
Email: kmaughn@statinmed.com

Website
https://statinmed.com/data/
Alternate Contact

STATinMED RWD Insights
Amy Rovi, SVP, Sales and Marketing
STATinMED, LLC
13101 Preston Rd Suite 110, #3395 
Dallas, TX 75240
USA
Phone: +1 214-480-4946
Email: arovi@statinmed.com

Source of Database Funding
Private

(STATinMED)

Sponsoring Government Agency
N/A

(Not applicable)

Sponsoring Pharmaceutical Manufacturer

N/A

(Not applicable)

Database Usage Restrictions
Private Access

Data access is restricted by licensing agreement; please contact database manager for more details.
Data are restricted to de-identified healthcare claims, e.g., patient identifiers are removed.
All data are in English.

Charge for Database Usage
Yes

Cost of data can be project-based, or licensed for a specific time period based on client needs

Data Media Format
PDF Files
Excel / CSV
FLAT files
Text files

NOTE: Results outputs can be delivered in reports in Word or PPT

Number of Publications Using Database
>10
References of Studies Using/Describing Database

1. Navari RM, Nelson WW, Shoaib S, Singh R, Zhang W, Bailey WL. Real-World Treatment Outcomes, Healthcare Resource Use, and Costs Associated with Antiemetics Among Cancer Patients on Cisplatin-Based Chemotherapy. Adv Ther. 2023 Jul;40(7):3217-3226.

2. Escobar M, Bullano M, Mokdad AG, Caicedo J, Schultz BG, Fan Q, Verma S. A real-world evidence analysis of the impact of switching from factor VIII to emicizumab prophylaxis in patients with hemophilia A without inhibitors. Expert Rev Hematol. 2023 Jun;16(6):467-474.

3. Terrault N, Dieyi C, Trivedi R, Coppola R, Maynard J, Reau N, Satram S, Chattergoon M. Prevalence of hepatitis B and D virus among a nationally representative insured population in the United States. AASLD The Liver Meeting. Boston, MA: Nov 10-14, 2023.

4. Karlitz J, Liu Y, Gupta P, Aweh G, Chung K. Burden of liver cancer among Medicaid-insured patients: A retrospective analysis of a national all-payer claims database. American College of Gastroenterology (ACG) Annual Scientific Meeting. Vancouver, CA: Oct 20-25, 2023.

5. Holman D, Drayton D, Pandit M, Diaz A, Maughn K, Dieyi C, Achter E, Peeples H. Effects of insurance coverage and antiseizure medication formulary policies on the experiences of patients with epilepsy and healthcare professionals: A qualitative study. Academy of Managed Care Pharmacy (AMCP) Nexus 2023. Orlando, FL: Oct 16-19, 2023.

6. Chung KC, Karlitz J, Liu Y, Gupta P, Aweh G. Cancer incidence among the Medicaid population: A retrospective analysis of a national all-payer claims database. Academy of Managed Care Pharmacy (AMCP) Nexus 2023. Orlando, FL: Oct 16-19, 2023.

7. Hendrix K, Feliciano J, Wassel C, Feld A, Maynard J, Batchu L, Lauterio M, Mohanty M, Dasenbrook E. Real-world disease burden and mortality associated with bronchiectasis. American College of Chest Physicians (CHEST) Annual Meeting. Honolulu, HI: Oct 8-11, 2023.

8. Sarafoglou K, Casteras A, Charlton RW, Barnes C, Dieyi C, Thornton P. Dose dependent risks of glucocorticoid treatment in classic CAH. European Society for Paediatric Endocrinology (ESPE). Hague, Netherlands: Sept 21-23, 2023.

9. Jagannath S, Kharat A, Fu AZ, Huo S, Kohli M, Adams S, Umeh E, Foster M. Healthcare resource utilization and costs among patients with relapsed/refractory multiple myeloma treated with chimeric antigen receptor-T (CAR-T) cell therapy. Annual Meeting of the Society of Hematologic Oncology (SOHO) 2023. Houston, TX: Sept 6-9, 2023.

10. Aksamit T, Wu J, Hassan M, Achter E, Chatterjee A. Impact of initiation of amikacin liposome inhalation suspension on hospitalizations and other healthcare resource utilization measures: a retrospective cohort study in real-world settings. BMC Pulm Med. 2022 Dec 3;22(1):461.

Database Contact
Database Contact Data

Keshia Maughn
SVP/Principal, RWE (STATinMED RWD Insights)
STATinMED, LLC
13101 Preston Rd Suite 110, #3395
Dallas, TX 75240
USA
Phone:+1 214-480-4946
Email: kmaughn@statinmed.com

Alternate Contact

STATinMED RWD Insights
Amy Rovi, SVP, Sales and Marketing
STATinMED, LLC
13101 Preston Rd Suite 110, #3395 
Dallas, TX 75240
USA
Phone: +1 214-480-4946
Email: arovi@statinmed.com

References of Studies Using/Describing Database

1. Navari RM, Nelson WW, Shoaib S, Singh R, Zhang W, Bailey WL. Real-World Treatment Outcomes, Healthcare Resource Use, and Costs Associated with Antiemetics Among Cancer Patients on Cisplatin-Based Chemotherapy. Adv Ther. 2023 Jul;40(7):3217-3226.

2. Escobar M, Bullano M, Mokdad AG, Caicedo J, Schultz BG, Fan Q, Verma S. A real-world evidence analysis of the impact of switching from factor VIII to emicizumab prophylaxis in patients with hemophilia A without inhibitors. Expert Rev Hematol. 2023 Jun;16(6):467-474.

3. Terrault N, Dieyi C, Trivedi R, Coppola R, Maynard J, Reau N, Satram S, Chattergoon M. Prevalence of hepatitis B and D virus among a nationally representative insured population in the United States. AASLD The Liver Meeting. Boston, MA: Nov 10-14, 2023.

4. Karlitz J, Liu Y, Gupta P, Aweh G, Chung K. Burden of liver cancer among Medicaid-insured patients: A retrospective analysis of a national all-payer claims database. American College of Gastroenterology (ACG) Annual Scientific Meeting. Vancouver, CA: Oct 20-25, 2023.

5. Holman D, Drayton D, Pandit M, Diaz A, Maughn K, Dieyi C, Achter E, Peeples H. Effects of insurance coverage and antiseizure medication formulary policies on the experiences of patients with epilepsy and healthcare professionals: A qualitative study. Academy of Managed Care Pharmacy (AMCP) Nexus 2023. Orlando, FL: Oct 16-19, 2023.

6. Chung KC, Karlitz J, Liu Y, Gupta P, Aweh G. Cancer incidence among the Medicaid population: A retrospective analysis of a national all-payer claims database. Academy of Managed Care Pharmacy (AMCP) Nexus 2023. Orlando, FL: Oct 16-19, 2023.

7. Hendrix K, Feliciano J, Wassel C, Feld A, Maynard J, Batchu L, Lauterio M, Mohanty M, Dasenbrook E. Real-world disease burden and mortality associated with bronchiectasis. American College of Chest Physicians (CHEST) Annual Meeting. Honolulu, HI: Oct 8-11, 2023.

8. Sarafoglou K, Casteras A, Charlton RW, Barnes C, Dieyi C, Thornton P. Dose dependent risks of glucocorticoid treatment in classic CAH. European Society for Paediatric Endocrinology (ESPE). Hague, Netherlands: Sept 21-23, 2023.

9. Jagannath S, Kharat A, Fu AZ, Huo S, Kohli M, Adams S, Umeh E, Foster M. Healthcare resource utilization and costs among patients with relapsed/refractory multiple myeloma treated with chimeric antigen receptor-T (CAR-T) cell therapy. Annual Meeting of the Society of Hematologic Oncology (SOHO) 2023. Houston, TX: Sept 6-9, 2023.

10. Aksamit T, Wu J, Hassan M, Achter E, Chatterjee A. Impact of initiation of amikacin liposome inhalation suspension on hospitalizations and other healthcare resource utilization measures: a retrospective cohort study in real-world settings. BMC Pulm Med. 2022 Dec 3;22(1):461.